



General Assembly

File No. 429

February Session, 2016

Substitute Senate Bill No. 129

Senate, April 4, 2016

The Committee on Insurance and Real Estate reported through SEN. CRISCO of the 17th Dist., Chairperson of the Committee on the part of the Senate, that the substitute bill ought to pass.

# AN ACT REQUIRING A STUDY OF ABUSE-DETERRENT AND NONABUSE-DETERRENT OPIOID ANALGESICS.

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. (Effective from passage) The Insurance Commissioner shall 2 study abuse-deterrent opioid analgesics and nonabuse-deterrent 3 opioid analgesics. Such study shall include, but not be limited to, (1) 4 the health insurance coverage in this state for each type of opioid 5 analgesic, (2) the frequency of dispensation of each type of opioid 6 analgesic over the twelve months immediately preceding, to the extent determinable, (3) manufacturer cost comparisons between each type of 8 opioid analgesic, (4) comparisons of out-of-pocket expenses to 9 insureds in this state for each type of opioid analgesic, and (5) the 10 availability of generic abuse-deterrent opioid analgesics, including a 11 summary of any guidance document published on the subject during 12 2015 and 2016 by the federal Food and Drug Administration. Not later 13 than January 1, 2017, the Insurance Commissioner shall submit a 14 report, in accordance with the provisions of section 11-4a of the general

sSB129 / File No. 429 1

sSB129 File No. 429

15 statutes, to the joint standing committee of the General Assembly

16 having cognizance of matters relating to insurance.

This act shall take effect as follows and shall amend the following sections:

Section 1 from passage New section

**PH** Joint Favorable C/R INS

**INS** Joint Favorable Subst.

sSB129 File No. 429

The following Fiscal Impact Statement and Bill Analysis are prepared for the benefit of the members of the General Assembly, solely for purposes of information, summarization and explanation and do not represent the intent of the General Assembly or either chamber thereof for any purpose. In general, fiscal impacts are based upon a variety of informational sources, including the analyst's professional knowledge. Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.

#### **OFA Fiscal Note**

### State Impact:

Agency Affected	Fund-Effect	FY 17 \$	FY 18 \$
Insurance Dept.	IF - Cost	Up to	None
		\$55,000	

Note: IF=Insurance Fund

## Municipal Impact: None

### Explanation

The bill requires the Insurance Department to study abuse-deterrent opioid analgesics and nonabuse-deterrent opioid analgesics and report to the Insurance Committee by January 1, 2017. The cost to the department is anticipated to be up to \$55,000 to hire a consultant to undertake the study.<sup>1</sup>

#### The Out Years

**State Impact:** None

Municipal Impact: None

<sup>&</sup>lt;sup>1</sup> This assumes consulting costs of approximately \$75 per hour, 30 hours per week for up to 24 weeks.

sSB129 File No. 429

# OLR Bill Analysis sSB 129

# AN ACT REQUIRING A STUDY OF ABUSE-DETERRENT AND NONABUSE-DETERRENT OPIOID ANALGESICS.

#### **SUMMARY:**

The Office of Legislative Research does not analyze Special Acts.

#### **COMMITTEE ACTION**

Public Health Committee

Insurance and Real Estate Committee

```
Joint Favorable Substitute
Yea 19 Nay 0 (03/15/2016)
```